Case report and review: IVIg and efgartigimod in Guillain-Barré with Graves disease and thyroid cancer
Doctors treat a rare relapse of Guillain-Barré syndrome with new immune therapies
This case report and literature review describes a 33-year-old man with Guillain-Barré syndrome, Graves disease, and papillary thyroid carci…
A 33-year-old man with Guillain-Barré syndrome found relief after doctors treated his underlying thyroid cancer and used new immune therapie…
Review synthesizes Treg biology and NB-UVB, JAK inhibitors, IL-2 in vitiligo patients
Review shows immune cells may be off in vitiligo
This narrative review examines Treg biology and immunoregulatory functions alongside NB-UVB, JAK inhibitors, and low-dose IL-2 in vitiligo p…
A review finds immune cells that calm inflammation are fewer and less effective in people with vitiligo, suggesting a path for future treatm…
Narrative review discusses CD40/CD40L signaling regulation in rheumatoid arthritis and other autoimmune conditions
Safer CD40/CD40L targeting needs selectivity for autoimmune diseases
This narrative review examines CD40/CD40L signaling regulation in rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome…
A narrative review suggests that safer therapeutic targeting of CD40/CD40L signaling will require greater selectivity to treat rheumatoid ar…
Narrative review on tumor antigen-associated autoantibodies in cancer diagnosis and treatment
Tumor antibodies show a complex dual role in cancer growth and defense
This narrative review synthesizes evidence on tumor antigen-associated autoantibodies (TAAbs) in cancer. The authors note TAAbs have a dual …
New review suggests tumor antibodies can both help and hinder cancer, though detection remains difficult for doctors to use right now.
Narrative review discusses antibody targeting of the TNF–TNFR2 axis in cancer with noted limitations
Antibodies targeting TNFR2 show promise for cancer treatment
This narrative review examines antibody targeting of the TNF–TNFR2 axis, including monoclonal antibodies, antibody–drug conjugates, and bisp…
A narrative review suggests antibodies targeting the TNF–TNFR2 axis may offer new cancer treatment options, though more research is needed.
Systematic review finds convalescent plasma does not reduce mortality in COVID-19
Convalescent plasma does not reduce COVID-19 death risk
This systematic review of 48 RCTs (24,518 participants) found that convalescent plasma does not reduce all-cause mortality or improve clinic…
A large review of 48 trials finds convalescent plasma doesn't lower death risk in moderate to severe COVID-19. For mild cases, evidence is u…
Immunocompetent tumor-on-a-chip platforms offer essential tools for understanding cancer-immune biology and accelerating personalized immunotherapy development
New chips mimic human tumors to test cancer drugs faster
Immunocompetent tumor-on-a-chip platforms provide essential tools for understanding cancer-immune biology. These advanced models accelerate …
Tiny chips that mimic human tumors could soon help doctors test new cancer drugs faster and more accurately than ever before.
Review discusses metabolic reprogramming of macrophages for sepsis-associated acute lung injury with noted limitations
Immune Cell Energy Switch Offers Hope Against Deadly Sepsis Lungs
This narrative review examines the concept of metabolic reprogramming of macrophages as a potential approach for sepsis-associated acute lun…
• Scientists reprogrammed immune cells to calm sepsis lung damage • Helps critically ill patients with few current options • Still in lab te…
Immediate smoking cessation support increases 12-month quit rates in adults with chronic airway diseases
Scheduling Quit Appointments Now Boosts Long-Term Success For Asthma Patients
This randomized trial in 397 adult smokers with asthma, COPD, or bronchiectasis compared immediate support with usual advice. The immediate …
Scheduling a quit clinic visit immediately after diagnosis doubles long-term success rates for people with asthma or COPD.
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma
Venetoclax combo shows promise for relapsed Hodgkin lymphoma
A 26-year-old with relapsed/refractory classical Hodgkin lymphoma achieved complete metabolic remission after 6 cycles of venetoclax, chidam…
A 26-year-old man with relapsed Hodgkin lymphoma achieved complete remission after a novel three-drug regimen, with no significant side effe…
Narrative review of Europe-licensed anti-asthmatic biologics for severe pediatric asthma notes limited pediatric evidence
Kids' Asthma Biologics Work Differently Than Adults Think
This narrative review examines the use of Europe-licensed anti-asthmatic biologics in pediatric patients with severe asthma. The authors hig…
• Biologics help severe childhood asthma but act unlike adult treatments • Young patients unresponsive to standard inhalers or steroids bene…
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…